Zydus Cadila Acquires US-Based Sentynl Therapeutics

New Delhi: Zydus Cadila on Thursday said it has acquired Sentynl Therapeutics, a US-based pharma company specialised in marketing of products in the pain management segment. The transaction will be EPS (earnings per share) accretive, Zydus Cadila said in a statement. With this acquisition, it said the company makes a foray into the specialty pain market in the US valued at $8 billion. "It gains access to the specialty distribution...